Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
TRIUMPH-1 (80 Weeks) The pivotal TRIUMPH-1 obesity trial (2,339 adults, no diabetes), presented at ADA 2026, extended the treatment window to 80 weeks and produced the largest pivotal weight-loss readout to date: Among the 12 mg group, 45.3% lost at least 30% of their body weight and 65.3% ended the trial with a BMI below 30
BMI 27.5 is the typical threshold in India
Side effects are generally mild and manageable, usually involving only mild gastrointestinal symptoms that resolve quickly
The bigger picture: endometriosis and metabolic health The GLP-1 and endometriosis connection is part of a larger scientific shift toward understanding endometriosis as a systemic metabolic and inflammatory disease rather than a purely reproductive condition
Reactivation of the totally inactive pancreatic lipase RP1 by structure-predicted point mutations
US$ 27.91
US$ 25.87
US$ 27.04
US$ 28.50
